{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:52:44Z","timestamp":1791553964144,"version":"4.3.4"},"reference-count":34,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,9,27]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bcr-2025-265927","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:30:20Z","timestamp":1791552620000},"page":"e265927","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Reversible cerebral vasoconstriction syndrome following selective serotonin reuptake inhibitor use"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-0921","authenticated-orcid":false,"given":"Amlan Kusum","family":"Datta","sequence":"first","affiliation":[{"name":"Neurology, Narayana Multispeciality Hospital Barasat, Barasat, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8963-3554","authenticated-orcid":false,"given":"Adreesh","family":"Mukherjee","sequence":"additional","affiliation":[{"name":"Neurology, Bangur institute of Neurosciences, IPGMER, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"2026100906301018000_19.10.e265927.1","doi-asserted-by":"publisher","DOI":"10.1177\/17474930231181250"},{"key":"2026100906301018000_19.10.e265927.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70135-7"},{"key":"2026100906301018000_19.10.e265927.3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/0971-3026.120258","article-title":"Call-Fleming syndrome","volume":"23","author":"Skandhan","year":"2013","journal-title":"Indian J Radiol Imaging"},{"key":"2026100906301018000_19.10.e265927.4","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1212\/WNL.0000000000012223","article-title":"Reversible Cerebral Vasoconstriction Syndrome: Symptoms, Incidence, and Resource Utilization in a Population-Based US Cohort","volume":"97","author":"Magid-Bernstein","year":"2021","journal-title":"Neurology"},{"key":"2026100906301018000_19.10.e265927.5","doi-asserted-by":"publisher","DOI":"10.1111\/head.12256"},{"key":"2026100906301018000_19.10.e265927.6","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.68"},{"key":"2026100906301018000_19.10.e265927.7","doi-asserted-by":"publisher","DOI":"10.1177\/1756285610361795"},{"key":"2026100906301018000_19.10.e265927.8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-1-200701020-00007"},{"key":"2026100906301018000_19.10.e265927.9","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-017-0460-7","article-title":"Reversible Cerebral Vasoconstriction Syndrome: Recognition and Treatment","volume":"19","author":"Cappelen-Smith","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"2026100906301018000_19.10.e265927.10","doi-asserted-by":"crossref","DOI":"10.1007\/s11916-020-00908-1","article-title":"Narrative Review: Headaches After Reversible Cerebral Vasoconstriction Syndrome","volume":"24","author":"Ling","year":"2020","journal-title":"Curr Pain Headache Rep"},{"key":"2026100906301018000_19.10.e265927.11","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.024416"},{"key":"2026100906301018000_19.10.e265927.12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1941874420953051","article-title":"Illicit Drugs and Reversible Cerebral Vasoconstriction Syndrome","volume":"11","author":"Short","year":"2021","journal-title":"Neurohospitalist"},{"key":"2026100906301018000_19.10.e265927.13","first-page":"32","article-title":"The Epidemiology of Reversible Cerebral Vasoconstriction Syndrome in Patients at a Colorado Comprehensive Stroke Center","volume":"10","author":"Jensen","year":"2018","journal-title":"J Vasc Interv Neurol"},{"key":"2026100906301018000_19.10.e265927.14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jaclp.2021.07.013","article-title":"Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine","volume":"62","author":"Manning","year":"2021","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"2026100906301018000_19.10.e265927.15","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm256"},{"key":"2026100906301018000_19.10.e265927.16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.pharmthera.2010.08.004","article-title":"Contribution of gene-modified mice and rats to our understanding of the cardiovascular pharmacology of serotonin","volume":"128","author":"Monassier","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2026100906301018000_19.10.e265927.17","doi-asserted-by":"publisher","DOI":"10.1111\/head.12202"},{"key":"2026100906301018000_19.10.e265927.18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10194-009-0117-3","article-title":"Reversible cerebral vasoconstriction syndrome: case report","volume":"10","author":"\u00d6z","year":"2009","journal-title":"J Headache Pain"},{"key":"2026100906301018000_19.10.e265927.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.1.130"},{"key":"2026100906301018000_19.10.e265927.20","doi-asserted-by":"crossref","unstructured":"Durmu\u015f B , Osse RJ , Emmer B , et al . Reversible Cerebral Vasoconstriction Syndrome and Monoamine Oxidase Inhibitors. Prim Care Companion CNS Disord 2016;18. doi:10.4088\/PCC.16l01945","DOI":"10.4088\/PCC.16l01945"},{"key":"2026100906301018000_19.10.e265927.21","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000223648.76430.27"},{"key":"2026100906301018000_19.10.e265927.22","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1097\/MJT.0000000000001082","article-title":"Vortioxetine-Related Call-Fleming Syndrome","volume":"28","author":"Moodliar","year":"2019","journal-title":"Am J Ther"},{"key":"2026100906301018000_19.10.e265927.23","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009701","article-title":"The reversible cerebral vasoconstriction syndrome in association with venlafaxine and methenamine","volume":"2013","author":"Davies","year":"2013","journal-title":"BMJ Case Rep"},{"key":"2026100906301018000_19.10.e265927.24","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/ccr3.1090","article-title":"A 31-year-old with idiopathic reversible cerebral vasoconstriction syndrome","volume":"5","author":"Qureshi","year":"2017","journal-title":"Clin Case Rep"},{"key":"2026100906301018000_19.10.e265927.25","doi-asserted-by":"publisher","DOI":"10.1177\/1941874413518639"},{"key":"2026100906301018000_19.10.e265927.26","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.09.2011.4841","article-title":"A reversible cerebral vasoconstriction syndrome","volume":"2012","author":"Ba","year":"2012","journal-title":"BMJ Case Rep"},{"key":"2026100906301018000_19.10.e265927.27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/2396987316656981","article-title":"Gender and hormonal influences in reversible cerebral vasoconstriction syndrome","volume":"1","author":"Topcuoglu","year":"2016","journal-title":"Eur Stroke J"},{"key":"2026100906301018000_19.10.e265927.28","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.01095.2005"},{"key":"2026100906301018000_19.10.e265927.29","doi-asserted-by":"crossref","DOI":"10.25259\/SNI_578_2019","article-title":"Reversible cerebral vasoconstriction syndrome concomitant with cerebral venous sinus thrombosis following ovarian tumor resection: A report of two cases","volume":"11","author":"Shimizu","year":"2020","journal-title":"Surg Neurol Int"},{"key":"2026100906301018000_19.10.e265927.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01868.x"},{"key":"2026100906301018000_19.10.e265927.31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/PRA.0000000000000811","article-title":"Management of Psychiatric Diagnoses in Reversible Cerebral Vasoconstriction Syndrome: The Dangers of Worsening Pathology with Serotonergic Medications: A Case Report and Literature Review","volume":"30","author":"Wang","year":"2024","journal-title":"J Psychiatr Pract"},{"key":"2026100906301018000_19.10.e265927.32","first-page":"5","article-title":"Overview of the mechanism of action of lithium in the brain: fifty-year update","volume":"61 Suppl 9","author":"Lenox","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"2026100906301018000_19.10.e265927.33","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-014-0437-9","article-title":"Thunderclap headache","volume":"14","author":"Dilli","year":"2014","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2026100906301018000_19.10.e265927.34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2022.12.002","article-title":"Levetiracetam induces severe psychiatric symptoms in people with epilepsy","volume":"116","author":"Tao","year":"2024","journal-title":"Seizure"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-265927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:30:33Z","timestamp":1791552633000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-265927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bcr-2025-265927"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-265927","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}